TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.